Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function

Journal of Inherited Metabolic Disease

Volumn 37, Issue 5, 2014, Pages 745-752

  Bartlett, David C ^a,b   Lloyd, Carla ^c   McKiernan, Patrick J ^c   Newsome, Phil N ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXANONE DERIVATIVE; ENZYME INHIBITOR; NITISINONE; NITROBENZOIC ACID DERIVATIVE;

ADOLESCENT; ADULT; CHILD; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY; LIVER TRANSPLANTATION; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TYROSINEMIAS; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYCLOHEXANONES; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; LIVER TRANSPLANTATION; MALE; NITROBENZOATES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TYROSINEMIAS; YOUNG ADULT;

EID: 84893167617     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9683-x     Document Type: Article

References (24)

1. al-Dhalimy M, Overturf K, Finegold M, Grompe M (2002) Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 75:38–45
2. Arnon R, Annunziato R, Miloh T et al (2011) Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database. Pediatr Transplant 15:400–405
3. Arora-Gupta N, Davies P, McKiernan P, Kelly DA (2004) The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 8:145–150
4. Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, Mckiernan PJ (2013) Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1. J Inherit Metab Dis 36:15–20
5. Baumann U, Duhme V, Auth MK, McKiernan PJ, Holme E (2006) Lectin-reactive alpha-Fetoprotein in patients with tyrosinemia Type I and hepatocellular carcinoma. J Pediatr Gastroenterol Nutr 43:77–82
6. Forget S, Patriquin HB, Dubois J et al (1999) The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatr Radiol 29:104–108
7. Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM (1994) A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 331:353–357
8. Holme E, Lindstedt S (2000) Nontransplant treatment of tyrosinemia. Clin Liver Dis 4:805–814
9. Hutchesson AC, Hall SK, Preece MA, Green A (1996) Screening for tyrosinaemia type I. Arch Dis Child Fetal Neonatal Ed 74:F191–F194
10. Laberge C, Grenier A, Valet JP, Morissette J (1990) Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I. Am J Hum Genet 47:325–328
11. Laine J, Salo MK, Krogerus L, Karkkainen J, Wahlroos O, Holmberg C (1995) The nephropathy of type I tyrosinemia after liver transplantation. Pediatr Res 37:640–645
12. Larochelle J, Alvarez F, Bussieres JF et al (2012) Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab 107:49–54
13. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813–817
14. Mckiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 66:743–750
15. Mieles LA, Esquivel CO, Van Thiel DH et al (1990) Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig Dis Sci 35:153–157
16. Mohan N, McKiernan P, Preece MA et al (1999) Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 158(Suppl 2):S49–S54
17. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266
18. Paradis K, Weber A, Seidman EG et al (1990) Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 47:338–342
19. Russo PA, Mitchell GA, Tanguay RM (2001) Tyrosinemia: a review. Pediatr Dev Pathol 4:212–221
20. Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am 34:571–590
21. Shoemaker LR, Strife CF, Balistreri WF, Ryckman FC (1992) Rapid improvement in the renal tubular dysfunction associated with tyrosinemia following hepatic replacement. Pediatrics 89:251–255
22. Tuchman M, Freese DK, Sharp HL, Ramnaraine ML, Ascher N, Bloomer JR (1987) Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation. J Pediatr 110:399–403
23. van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA (2005) Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 40:90–93
24. Weinberg AG, Mize CE, Worthen HG (1976) The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 88:434–438